XERS

Xeris Biopharma Holdings, Inc. Common Stock

9.10

USD

+0.15

+1.68%

Sep 25, 15:59 UTC -4

Closed

After-Market

9.11

+0.01

+0.15%

XERS Earnings Reports

Positive Surprise Ratio

XERS beat 18 of 33 last estimates.

55%

Next Report

Date of Next Report

Nov 04, 2026

Estimate for Q3 26 (Revenue/ EPS)

$103.38M

$0.02

Implied change from Q2 26 (Revenue/ EPS)

+12.24%

-111.11%

Implied change from Q3 25 (Revenue/ EPS)

+38.98%

Xeris Biopharma Holdings, Inc. Common Stock earnings per share and revenue

On Aug 06, 2026, XERS reported earnings of -0.18 USD per share (EPS) for Q2 26, missing the estimate of 0.00 USD, resulting in a -5394.12% surprise. Revenue reached 92.10 million, compared to an expected 92.03 million, with a 0.08% difference. The market reacted with a -9.25% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 6 analysts forecast an EPS of 0.02 USD, with revenue projected to reach 103.38 million USD, implying an decrease of -111.11% EPS, and increase of 12.24% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

PharmaCyte Biotech, Inc. Common Stock

Report Date

Sep 14, 2026 For Q1 27

Estimate

Actual

-$0.54

Surprise

FAQ

What were Xeris Biopharma Holdings, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Xeris Biopharma Holdings, Inc. Common Stock reported EPS of -$0.18, missing estimates by -5394.12%, and revenue of $92.10M, 0.08% above expectations.

How did the market react to Xeris Biopharma Holdings, Inc. Common Stock's Q2 2026 earnings?

The stock price moved down -9.25%, changed from $8.11 before the earnings release to $7.36 the day after.

When is Xeris Biopharma Holdings, Inc. Common Stock expected to report next?

The next earning report is scheduled for Nov 04, 2026.

What are the forecasts for Xeris Biopharma Holdings, Inc. Common Stock's next earnings report?

Based on 6 analysts, Xeris Biopharma Holdings, Inc. Common Stock is expected to report EPS of $0.02 and revenue of $103.38M for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.